Budésonide et formotérol : interactions médicamenteuses

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (notice Abiratérone, Mises en garde et précautions)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Adalimumab, Mise en garde encadrée)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Inhaled beta agonist: salmeterol ↑ salmeterol Coadministration of salmeterol with REYATAZ is not recommended. (notice Atazanavir, Interactions médicamenteuses)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (notice Axitinib, Mises en garde et précautions)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (notice Budésonide et formotérol, Mises en garde et précautions)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Baricitinib, Mise en garde encadrée)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled medications, budesonide and formoterol fumarate dihydrate can produce paradoxical bronchospasm, which may be life threatening. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (notice Cocaïne, Mises en garde et précautions)

Inhaled beta agonist : salmeterol ↑ salmeterol Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. (notice Darunavir, Interactions médicamenteuses)

Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. (notice Darunavir et cobicistat, Interactions médicamenteuses)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (notice Dronabinol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Inhaled Beta Agonist: salmeterol ↑ salmeterol Coadministration of salmeterol and GENVOYA is not recommended. (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (notice Emtricitabine, rilpivirine et ténofovir, Contre-indications)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Étanercept, Mise en garde encadrée)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (notice Budésonide et formotérol, Mises en garde et précautions)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (notice Budésonide et formotérol, Mises en garde et précautions)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended. (notice Fosamprénavir, Interactions médicamenteuses)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (notice Imipramine, Interactions médicamenteuses)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Infliximab, Mise en garde encadrée)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Kétoconazole, Interactions médicamenteuses)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (notice Liothyronine, Mise en garde encadrée)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (notice Lovastatine, Contre-indications)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (notice Mifépristone, Mise en garde encadrée)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (notice Mitotane, Mise en garde encadrée)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (notice Moexipril, Mises en garde)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (notice Phénelzine, Contre-indications)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (notice Ribavirine, Mise en garde encadrée)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (notice Rilpivirine, Contre-indications)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (notice Roflumilast, Mises en garde et précautions)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (notice Budésonide et formotérol, Mises en garde et précautions)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (notice Sirolimus, Mises en garde et précautions)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (notice Somatropine, Interactions médicamenteuses)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tocilizumab, Mise en garde encadrée)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tofacitinib, Mise en garde encadrée)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (notice Trandolapril, Mises en garde)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (notice Tranylcypromine, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (notice Trioxyde d'arsenic, Mise en garde encadrée)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Upadacitinib, Mise en garde encadrée)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide alendronique, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide ibandronique, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (notice Acide méfénamique, Mises en garde et précautions)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (notice Acide pamidronique, Mises en garde et précautions)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (notice Acide risédronique, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (notice Acide zolédronique, Mises en garde et précautions)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (notice Afatinib, Mises en garde et précautions)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (notice Albendazole, Mises en garde et précautions)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (notice Alemtuzumab, Mises en garde et précautions)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (notice Aliskirène, Mises en garde et précautions)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (notice Alogliptine et metformine, Interactions médicamenteuses)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (notice Amphotéricine B, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (notice Aspirine, Mises en garde)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (notice Atomoxétine, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Belladone et opium, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (notice Bendamustine, Mises en garde et précautions)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (notice Benralizumab, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (notice Bortézomib, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine et naloxone, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butorphanol, Mises en garde)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (notice Céfoxitine, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Célécoxib, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ciprofloxacine, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (notice Cladribine, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Codéine, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (notice Cytarabine, Mises en garde)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (notice Daptomycine, Mises en garde et précautions)

Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive… (notice Déférasirox, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (notice Dénosumab, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (notice Désogestrel et éthinylestradiol, Précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

The amount of both steroids should be considered in the choice of an oral contraceptive. (notice Diacétate d'étynodiol et éthinylestradiol, Mises en garde)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac et misoprostol, Mises en garde et précautions)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (notice Dicyclovérine, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Diflunisal, Mises en garde)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (notice Digoxine, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (notice Doxapram, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (notice Dupilumab, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (notice Erlotinib, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estradiol, Précautions)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (notice Estradiol et diénogest, Interactions médicamenteuses)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estradiol et noréthistérone, Mises en garde et précautions)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (notice Estrogènes conjugués, Précautions)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estrogènes conjugués et bazédoxifène, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Étodolac, Mises en garde)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (notice Étravirine, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Fénoprofène, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Fentanyl, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (notice Fingolimod, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (notice Flurbiprofène, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (notice Glimépiride, Interactions médicamenteuses)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (notice Glipizide, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (notice Halopéridol, Interactions médicamenteuses)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (notice Hydralazine, Mises en garde)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et homatropine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et ibuprofène, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et paracétamol, Mises en garde)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydromorphone, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène et famotidine, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Indométacine, Mises en garde et précautions)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline asparte, Interactions médicamenteuses)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline dégludec, Interactions médicamenteuses)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline détémir, Interactions médicamenteuses)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline glargine, Interactions médicamenteuses)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline lispro, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (notice Ivermectine, Mises en garde)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (notice Kétamine, Mises en garde et précautions)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (notice Kétoprofène, Mises en garde et précautions)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Kétorolac, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Lévofloxacine, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (notice Lévonorgestrel et éthinylestradiol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Lévorphanol, Mises en garde)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (notice Lévothyroxine, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (notice Margétuximab, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (notice Médroxyprogestérone, Mises en garde et précautions)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (notice Mégestrol, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Méloxicam, Mises en garde et précautions)

Decrease corticosteroids gradually, if appropriate. (notice Mépolizumab, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Méthadone, Mises en garde et précautions)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (notice Méthazolamide, Interactions médicamenteuses)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (notice Méthotrexate, Interactions médicamenteuses)

If not, corticosteroids may be given and other causes of anemia should be considered. (notice Méthyldopa, Mises en garde)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

This can be corrected by giving appropriate doses of corticosteroids. (notice Métyrapone, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Inhaled corticosteroid may be reduced gradually. (notice Montélukast, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Morphine, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Moxifloxacine, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Nabumétone, Mises en garde)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Nalbuphine, Mises en garde)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène et ésoméprazole, Mises en garde et précautions)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (notice Natalizumab, Mises en garde et précautions)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (notice Natéglinide, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (notice Ocrélizumab, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ofloxacine, Mises en garde)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Olicéridine, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (notice Omalizumab, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Oxaprozine, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone et paracétamol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxymorphone, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Paracétamol et codéine, Mises en garde)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Paracétamol et ibuprofène, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (notice Pasiréotide, Mises en garde et précautions)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (notice Pénicillamine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Pentazocine et naloxone, Mises en garde)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Péthidine, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de glycérol, Interactions médicamenteuses)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de sodium, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Piroxicam, Mises en garde et précautions)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (notice Ponésimod, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (notice Budésonide et formotérol, Interactions médicamenteuses)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (notice Propofol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (notice Rifampicine, Interactions médicamenteuses)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (notice Rifapentine, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (notice Rocuronium, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Salsalate, Mises en garde)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Sulindac, Mises en garde)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Sumatriptan et naproxène, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (notice Suxaméthonium, Interactions médicamenteuses)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tapentadol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (notice Témozolomide, Mises en garde et précautions)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (notice Temsirolimus, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (notice Testostérone, Mises en garde et précautions)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (notice Théophylline, Mises en garde)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (notice Tolcapone, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Tolmétine, Mises en garde)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol et paracétamol, Mises en garde et précautions)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (notice Budésonide et formotérol, Mises en garde et précautions)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (notice Warfarine, Interactions médicamenteuses)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (notice Zanamivir, Mises en garde et précautions)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (notice Zénocutuzumab, Mises en garde et précautions)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (notice Budésonide et formotérol, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (notice Acarbose, Interactions médicamenteuses)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (notice Acide bempédoïque, Mises en garde et précautions)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (notice Altéplase, Mises en garde et précautions)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (notice Amikacine, Mises en garde et précautions)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (notice Budésonide et formotérol, Mises en garde et précautions)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Ampicilline, Mises en garde)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (notice Bévacizumab, Mises en garde et précautions)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (notice Bromocriptine, Interactions médicamenteuses)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (notice Busulfan, Mises en garde)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (notice Calcitriol, Interactions médicamenteuses)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfaclor, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfadroxil, Mises en garde et précautions)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefdinir, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfotétan, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefprozil, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Ceftazidime, Mises en garde)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (notice Ceftriaxone, Mises en garde et précautions)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (notice Clofarabine, Mises en garde et précautions)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (notice Clomifène, Mises en garde)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (notice Budésonide et formotérol, Mises en garde et précautions)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (notice Corticotropine, Mises en garde et précautions)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Dapagliflozine et metformine, Interactions médicamenteuses)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (notice Dropéridol, Interactions médicamenteuses)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (notice Drospirénone et éthinylestradiol, Mises en garde et précautions)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (notice Budésonide et formotérol, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Empagliflozine et metformine, Interactions médicamenteuses)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Étonogestrel et éthinylestradiol, Interactions médicamenteuses)

Steroids may or may not be effective in controlling these hemolytic episodes. (notice Fludarabine, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glibenclamide, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Glibenclamide et metformine, Interactions médicamenteuses)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glipizide et metformine, Précautions)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (notice Glucagon, Mises en garde et précautions)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (notice Guselkumab, Mises en garde et précautions)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (notice Insuline rapide (humaine), Mises en garde et précautions)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (notice Lénalidomide, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Linagliptine et metformine, Interactions médicamenteuses)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (notice Melphalan, Mises en garde)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Metformine, Interactions médicamenteuses)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (notice Méthohexital, Mises en garde)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (notice Budésonide et formotérol, Mises en garde et précautions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (notice Mitoxantrone, Interactions médicamenteuses)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (notice Naltrexone, Mises en garde et précautions)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norelgestromine et éthinylestradiol, Interactions médicamenteuses)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (notice Noréthistérone et éthinylestradiol, Mises en garde et précautions)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norgestimate et éthinylestradiol, Interactions médicamenteuses)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norgestrel et éthinylestradiol, Précautions)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (notice Oxacilline, Mises en garde)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (notice Pénicilline G, Mises en garde)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Pénicilline V, Mises en garde)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Pioglitazone et metformine, Interactions médicamenteuses)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Propylthiouracile, Mises en garde)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (notice Quinine, Interactions médicamenteuses)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (notice Raloxifène, Interactions médicamenteuses)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Répaglinide, Interactions médicamenteuses)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (notice Rituximab, Mises en garde et précautions)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Saxagliptine et metformine, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Sitagliptine et metformine, Interactions médicamenteuses)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (notice Ténectéplase, Mises en garde et précautions)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Thiamazole, Mises en garde)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (notice Budésonide et formotérol, Mises en garde et précautions)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (notice Ustékinumab, Mises en garde et précautions)

Les corticoïdes tels que la prednisone réduisent l'absorption du calcium et perturbent le métabolisme de la vitamine D, ce qui contribue à la perte osseuse. (NIH Office of Dietary Supplements, Vitamin D)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (notice Budésonide et formotérol, Mises en garde et précautions)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (notice Budésonide et formotérol, Mises en garde et précautions)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (notice Ziprasidone, Mises en garde et précautions)